secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2025-07-09T23:59:59+00:00
Accession:  0001558370-25-009139
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia doses first patient in 48 mg MAD cohort of Phase 1 obesity trial; Q4 top-line data expected
--------------------------------------------------------------------------------

- First patient dosed in 48 mg multiple ascending dose cohort of DA-1726 (GLP1R/GCGR dual agonist) for obesity.
- Prior 32 mg data: mean weight loss 4.3%, max 6.3% at Day 26 (p=0.0005); 83% early satiety; average waist reduction 1.6 inches by Day 33.
- Fasting glucose reduced up to 18 mg/dL without hypoglycemia; no QTcF prolongation; mild GI side effects, suggesting favorable tolerability.
- CEO stated DA-1726 has best-in-class potential with no titration needed; top-line results from 48 mg cohort expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837025009139/0001558370-25-009139-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837025009139/mtva-20250709x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-009139

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer